Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
A Midday Symposium to be Conducted at the 2019 ASHP Midyear Clinical Meeting & Exhibition
Monday, December 9, 2019, 11:30 AM - 1:00 PM PT
Mandalay Bay North Convention Center - South Pacific B, Lower Level
|Co-produced by ProCE, the Society of Infectious Diseases Pharmacists (SIDP), and the National Association of Specialty Pharmacy (NASP).|
Human immunodeficiency virus (HIV) research is undergoing an era of rapid change
and advancement in treatment approaches. Historically complex drug regimens are being
simplified, less-toxic alternative therapies are proving equally effective to older
agents, and novel dosage forms on the horizon are expected to impact patient care
and outcomes. Advances in therapeutic approaches have allowed patients living with
HIV to lead fairly normal lives without the disease significantly interfering with
quality of life and the potential to entirely halt progression. However, staying informed
about the latest recommendations and newly available drugs and drug combinations is
often challenging for many pharmacy professionals.
This session will discuss strategies to identify patients at risk for HIV and implement screening guideline recommendations. Current recommendations for treatment initiation and regimen selection in patients with co-morbidities or previous treatment failures will be discussed, including dosing and monitoring requirements. A focus on recently approved therapies and emerging treatment options will be presented. The activity will also address principles for PEP and PrEP prescribing and monitoring schedules.
The target audience for this activity includes clinical pharmacists, community pharmacists, specialty pharmacists, and managed care professionals. At the completion of this activity, the participant will be better able to:
10:45 AM Doors Open
11:30 AM – 1:00 PM CE Activity
Pre-registration is encouraged, and will be used for planning purposes. Seating will be available on a first-come, first-served basis. On-site registration will be available, space permitting. Food and beverages are not provided at Midday Symposia. This ASHP policy considers the varied internal policies of commercial supporters related to the Physician Payments Sunshine Act. You are welcome to bring your lunch to the session.
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Professor of Clinical Pharmacy
UCSF School of Pharmacy
Pharmacist, UCSF Womens HIV Program
San Francisco, California
Jason J. Schafer, PharmD, MPH, BCPS AQ-ID, BCIDP, AAHIVP
Professor and Vice Chair
Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
This activity is jointly provided by ProCE, Inc., the Society of Infectious Diseases Pharmacists, and the National Association of Specialty Pharmacy. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-502-L02-P has been assigned to this live knowledge-based activity (initial release date 12-09-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Cocohoba has no relevant commercial or financial relationships to disclose. Dr. Schafer is an advisory board member for Merck, and has received research grant funding as a primary investigator for Gilead and Merck. A portion of grant funds received by ProCE from Merck and ViiV Healthcare will be used to compensate the faculty for this presentation.
This activity is supported by an educational grant from Merck and ViiV Healthcare.
Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.